Definitions Section. Target Nomination Response Period 3.3(b)(i) Target Rejection Prohibition 3.3(b)(i) Target Selection Notice 3.3(c) Technology Transfer Requirements 3.1(d) Term 13.1 Terminated Compounds 13.6(a)(i) Terminated Products 13.6(a)(i) Terminated Program 13.6(a)(i) Terminated Target 13.6(a)(i) Termination Notice 13.3(a) Title 11 17.3(a) Transfer Record 3.6 Unmodified [*] CAR T-Cell Therapy 3.1(a)(i)(2) Waiver Terms 8.7(b)
Appears in 2 contracts
Sources: Collaboration and License Agreement (Lyell Immunopharma, Inc.), Collaboration and License Agreement (Lyell Immunopharma, Inc.)